Clinical effect of fludarabine combined with cyclophosphamide on chronic lymphocytic leukemia

Objective To evaluated the clinical efficacy of fludarabine combined with cyclophosphamide on chronic lymphocytic leukemia and the effect on peripheral blood Th17 and Treg cell ratio. Methods Two hundred patients were randomly divided into control group( n = 100) and treatment group( n = 100). Patients in control group intravenously given fludarabine 25 mg · m~(-2)on 1- 3 d; patients in treatment group were intravenously given fludarabine 25 mg·m~(-2)and cyclophosphamide 250mg· m~(-2)on 1- 3 d. A cycle of both groups were 4 weeks,and all treated for 2 cycles. The clinical efficacy,incidence of adverse drug reactions,and the ratio of Th17 and Treg cells in peripheral blood were observed. Results The total improvement rate of treatment group was98. 0%, higher than that in control group, which was 72. 0%( P 0. 05). The incidence of adverse drug reactions in treatment group was 8. 0%, significantly lower than 29. 0% in control group( P 0. 05). The Th17 cells and Treg cells in treatment group were significantly better than those in control group( P 0. 05).Conclusion Fludarabine combined with cyclophosphamide had a good clinical efficiency on chronic lymphocytic leukemia,which reduced the risk of adverse reactions and can significantly improve the Th17 and Treg cells in peripheral blood.